Zollinger-Ellison Syndrome: Symptoms, Diagnosis & Treatment

Zollinger–Ellison syndrome describes the clinical consequences of a gastrin-excess state: ectopic gastrin from a well-differentiated neuroendocrine tumour (gastrinoma) chronically stimulates parietal cells, producing basal acid hypersecretion that outpaces mucosal defence. The duodenal bulb and contiguous stomach bear the brunt, but acid and bile injury can extend distally when secretion is massive, producing jejunal ulcers that should always prompt reconsideration of hypersecretory physiology beyond routine gastritis or uncomplicated gastroesophageal reflux disease.

Unlike physiologic post-prandial gastrin release, tumour-driven secretion is autonomous and sustained, so histamine-2 blockade alone is usually inadequate once disease is florid. Nurses should conceptualise ZES as a paired problem—acid-driven mucosal injury plus secretory diarrhoea and electrolyte wasting—both of which need parallel monitoring while definitive tumour localisation and surgery discussions proceed.

Sporadic gastrinomas cluster in the duodenal submucosa or pancreatic parenchyma; lymph-node-only disease is recognised in expert series and influences pre-test probability for imaging. Roughly a fifth of patients harbour multiple endocrine neoplasia type 1 (MEN1), where multifocal small duodenal tumours coexist with parathyroid and pituitary disease risk—operative cure of acid hypersecretion is less common than in sporadic cases, so teams emphasise durable medical control with selective debulking of dominant lesions.

↔On a small screen, swipe or scroll sideways to see the full table.

Presentation blends acid injury and secretory sequelae; diarrhoea may dominate when mucosal ulceration is surprisingly modest.

Typical features

• Refractory dyspepsia, post-prandial burning or nocturnal pain out of proportion to endoscopic findings of uncomplicated oesophagitis.
• Multiple ulcers, unusual sites or rapid recurrence after therapy aimed at standard peptic ulcer disease.
• Watery diarrhoea, steatorrhoea pattern from pancreatic lipase inactivation in an acid-loaded duodenum.
• GERD-like symptoms refractory to conventional PPI dosing—often the clue that prompts high-dose PPIs trials before biochemical testing matures.

Atypical or late cues

• Isolated weight loss with normal appetite when diarrhoea is minimised by self-directed fasting.
• Neuroglycopenia is not expected—if confusion dominates, search alternative aetiologies while still correcting electrolytes.
• Jaundice or cholangitis picture if pancreatic head mass compresses bile ducts—coordinate urgent imaging.

Gastrinomas arise sporadically or in the context of MEN1 germline pathogenic variants. The functional biology is ectopic gastrin secretion; tumour grade and Ki-67 influence long-term behaviour but do not change the acute need for acid control. Chronic PPI exposure does not cause gastrinoma but obscures diagnosis—always document duration and dose when constructing timelines for endocrine review.

Pancreatic neuroendocrine overlap with pancreatic cancer is anatomical only; adenocarcinoma management differs—accurate biopsy and immunohistochemistry remain pathology tasks, but nurses should ensure specimens and imaging travel with the patient between referring and quaternary centres.

Clinical assessment

Quantify PPI dose, timing and OTC use; record NSAID exposure, prior H. pylori results, alcohol, family endocrine history and prior upper endoscopy (EGD) reports. Perform a structured abdominal assessment and trend vital signs when diarrhoea is volumetric.

Laboratory investigations

• Fasting gastrin on a protocolised fast with simultaneous acid assessment where available; repeat off PPI when bleeding risk allows.
• Secretin stimulation testing—a rise in gastrin after secretin supports gastrinoma physiology; arrange only through accredited labs.
• Electrolyte panel for hypokalaemia, hypomagnesaemia and renal impact of diarrhoea.
• Liver function tests when hepatic metastases are suspected.

Imaging and endoscopy

EGD documents ulcer burden and allows targeted biopsies; cross-sectional abdominal CT and MRI pursue gastrinoma localisation; endoscopic ultrasound is frequently decisive for small duodenal lesions. Functional scans (somatostatin receptor–based PET/CT where funded) refine metastatic mapping.

1. Stabilise acid complications: Initiate or escalate high-dose PPIs, correct electrolyte deficits (see laboratory list above), transfuse if bleeding, and avoid unsupervised PPI withdrawal.
2. Biochemical confirmation: Repeat fasting gastrin with documented acid status; schedule secretin testing when the pre-test probability remains high.
3. Genetic triage: Screen for MEN1 features—coordinate calcium/PTH testing and genetics counselling per protocol.
4. Imaging ladder: Multiphase CT/MRI → EUS; add receptor imaging when metastatic disease influences therapy.
5. Definitive therapy selection: Refer resectable sporadic disease early; in MEN1 or metastases, align on SSA, cytoreduction or systemic trials.
6. Safety-net: Provide explicit triggers for ED return (blood in vomit, syncope, rigid abdomen, uncontrolled diarrhoea).

↔On a small screen, swipe or scroll sideways to see the full table.

First-line acid suppression

High-dose scheduled PPI remains the backbone—dose titration is clinical, guided by symptom control, ulcer healing on repeat EGD and electrolyte tolerance. Long-term therapy demands bone health, B12 and magnesium surveillance per local monographs. Esomeprazole and omeprazole are commonly cited exemplars (see Key Takeaways for formulary links) but follow local equivalents.

Somatostatin analogues

Octreotide or long-acting SSA formulations can blunt hormone secretion when tumours are unresectable or while awaiting surgery—monitor glucose and gallbladder complications per endocrinology.

Surgery and liver-directed care

Enucleation or pancreaticoduodenectomy is selected for sporadic localised disease when imaging and MDT agree on resectability; liver metastases may warrant ablation, resection or embolisation alongside systemic therapy. Always reconcile anticoagulation and nutrition before major resections.

• Medication reconciliation: Capture every PPI source—including OTC—and align with planned fasting gastrin / secretin testing windows.
• Fluid and stool charting: Large-volume diarrhoea should trigger paired potassium checks and IV replacement protocols.
• Pre-endoscopy readiness: For urgent EGD in bleeding, maintain two large-bore lines, group-and-save and documented anticoagulant last dose.
• Education: Teach patients not to self-hold PPIs without a plan; explain why PPI washout is timed with the endocrine team.
• MDT documentation: Upload imaging discs, tumour board outcomes and SSA start dates into the legal record for continuity.

• Upper GI haemorrhage requiring endoscopic therapy and high-dose IV PPI bundles.
• Perforation or penetration with peritonitis or pancreatic fistula risk.
• Stricture or inflammatory gastric outlet obstruction—may require nasogastric tube insertion for decompression pending surgery.
• Metastatic liver disease driving refractory secretory state.

There is no community prevention for sporadic gastrinoma; clinician-facing prevention means early recognition of hypersecretory patterns, genetic counselling for MEN1 families, and preventing iatrogenic harm from inappropriate PPI cessation or under-treatment of bleeding while pursuing diagnosis.

Complete resection of sporadic gastrinoma can normalise gastrin and allow PPI down-titration, though late recurrence mandates surveillance. MEN1-associated disease behaves more indolently but is rarely cured by surgery alone; long-term biochemical control is the realistic goal. Metastatic well-differentiated NETs may demonstrate prolonged survival with multimodal therapy—avoid nihilistic framing while remaining honest about treatment burden.

Bedside monitoring checklist

• Strict stool frequency/volume and cramping scores alongside vital signs when initiating SSA.
• Daily weight and postural BP if diarrhoea causes intravascular depletion.
• Magnesium and glucose when on high-dose PPI plus octreotide.
• Pain scores after meals—rising epigastric scores may herald new perforation risk.

Communication

Use teach-back for complex medication calendars involving high-dose PPIs, bridging H2 blockers and planned secretin testing days. Escalate language barriers to professional interpreters when discussing surgery trade-offs.

• Massive GI bleeding, syncope or haemodynamic instability.
• Suspected perforation with peritonism or free air.
• Severe hypokalaemia with ECG changes or weakness.
• Inability to tolerate oral fluids with ongoing secretory losses.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response and matrix matching on the topic of fasting gastrin, secretin testing, high-dose PPIs, imaging for gastrinoma, MEN1 context and surgery triage—mirroring Clinical Judgment Measurement Model cues for acid hypersecretion syndromes.